Aravive, Inc. Uncategorized Contracts & Agreements

Offer Letter, dated April 10, 2023, by and between Aravive, Inc. and Maria Carolina Petrini (Filed With SEC on April 11, 2023)

Description of Capital Securities (Filed With SEC on March 15, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Leonard Scott Dove, Ph.D (Filed With SEC on February 6, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Robert Geller, M.D (Filed With SEC on February 6, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and RudyHoward (Filed With SEC on February 6, 2023)

Amendment No. 3 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Gail McIntyre, Ph.D (Filed With SEC on February 6, 2023)

Form of Side Letter Agreement by and among Aravive, Inc. and the BVF Investor party thereto (Filed With SEC on October 26, 2022)

Form of Side Letter Agreement by and among Aravive, Inc. and the persons party thereto (Filed With SEC on October 26, 2022)

Offer Letter, dated June 13, 2022, by and between Aravive, Inc. and Dr. Robert B. Geller (Filed With SEC on July 5, 2022)

Offer Letter, dated June 2, 2022, by and between Aravive, Inc. and Rudy C. Howard (Filed With SEC on June 3, 2022)

Offer Letter between Leonard Scott Dove, Ph.D. and Aravive, Inc (Filed With SEC on March 22, 2022)

Offer Letter, dated September 8, 2020 between Reshma Rangwala and the Company (Filed With SEC on March 16, 2021)

Description of Capital Securities (Filed With SEC on March 16, 2021)

Amendment to Offer Letter dated as of January 25, 2021 by and between Aravive, Inc. and Gail McIntyre, Ph.D (Filed With SEC on January 27, 2021)

Amendment to Offer Letter dated as of April 8, 2020 by and between the Company and Gail McIntyre (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Robert Hoffman (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Jay Shepard (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Srini Akkaraju (Filed With SEC on April 9, 2020)

Offer Letter, dated March 26, 2020 between Gail McIntyre and Aravive, Inc (Filed With SEC on March 27, 2020)

Offer Letter, dated March 26, 2020, between Vinay Shah and Aravive, Inc (Filed With SEC on March 27, 2020)

Description of Capital Securities (Filed With SEC on March 27, 2020)

Offer Letter, dated January 8, 2020, between Rekha Hemrajani and Aravive, Inc (Filed With SEC on January 9, 2020)

Amendment to Jay Shepard Offer Letter dated as of February 28, 2019 (Filed With SEC on March 6, 2019)

Offer Letter dated January 1, 2017 by and between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)

Offer Letter dated February 1, 2017 and the amendment thereto dated May 30, 2018 by and between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)

Amendment to Jay Shepard Offer Letter dated as of February 6, 2019 (Filed With SEC on February 12, 2019)

Cancer Research Grant Contract, dated December 1, 2015, by and between the Cancer Prevention and Research Institute of Texas and Ruga Corporation (Filed With SEC on August 3, 2018)

Form of Support Agreement, by and between Aravive Biologics, Inc. and Versartis, Inc.s directors, officers and certain stockholders (Filed With SEC on June 4, 2018)

Form of Support Agreement, by and between Versartis, Inc. and Aravive Biologics, Inc.s directors, officers and certain stockholders (Filed With SEC on June 4, 2018)

Offer Letter with Robert Gut, dated August 30, 2017 (Filed With SEC on March 6, 2018)

AMUNIX OPERATING INC. 500 Ellis Street Mountain View, CA 94043 (Filed With SEC on August 7, 2017)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 02/16/2016 (Filed With SEC on May 4, 2016)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 02/27/2015 (Filed With SEC on May 4, 2016)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 May 12, 2015 (Filed With SEC on August 5, 2015)

4200 Bohannon Drive, Suite 250 | Menlo Park, CA 94025 | 650 ###-###-#### (main) (Filed With SEC on August 5, 2015)

TECHNOLOGY TRANSFER AND CLINICAL SUPPLYAGREEMENT (Filed With SEC on March 19, 2014)

AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED LICENSING AGREEMENT (Filed With SEC on March 6, 2014)

VERSARTIS, INC. 500 ELLIS STREET MOUNTAIN VIEW, CA 94043 February 10, 2011 (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 275 SHORELINE DRIVE, SUITE 450 REDWOOD CITY, CA 94065 November 8, 2013 (Filed With SEC on February 18, 2014)

VERSARTIS, INC. December 20, 2010 (Filed With SEC on February 18, 2014)